Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
Completed
To determine response rate, median time to tumor progression, qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposi's sarcoma (KS) administered a 3-hour infusion of paclitaxel every 14 days. To evaluate the clinical benefit of paclitaxel in this patient population by evaluating self-reported responses to the Symptom Distress Scale and by documenting and evaluating any changes in their lymphedema, pain and disfiguring facia... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2005
Locations: Massachusetts Gen Hosp / AIDS Oncology Research, Boston, Massachusetts
Conditions: Sarcoma, Kaposi, HIV Infections